vx 497 has been researched along with gsk 369796 in 1 studies
| Studies (vx 497) | Trials (vx 497) | Recent Studies (post-2010) (vx 497) | Studies (gsk 369796) | Trials (gsk 369796) | Recent Studies (post-2010) (gsk 369796) |
|---|---|---|---|---|---|
| 25 | 3 | 7 | 6 | 0 | 3 |
| Protein | Taxonomy | vx 497 (IC50) | gsk 369796 (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 3 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 7.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernatchez, JA; Li, J; Li, R; Luan, Y; Siqueira-Neto, JL; Tran, LT | 1 |
1 review(s) available for vx 497 and gsk 369796
| Article | Year |
|---|---|
Drugs for the Treatment of Zika Virus Infection.
Topics: Animals; Antiviral Agents; Drug Development; Drug Discovery; Humans; Viral Vaccines; Zika Virus; Zika Virus Infection | 2020 |